[Form 4] AGRIFORCE GROWING SYSTEMS LTD. Insider Trading Activity
Rhea-AI Filing Summary
William John Meekison, a director of Agriforce Growing Systems Ltd. (AGRI), reported a purchase of 42,194 common shares on 09/18/2025 at a price equal to the 09/17/2025 closing price of $2.37, resulting in beneficial ownership of 42,194 shares held directly. The filing also discloses derivative grants: an acquisition on 09/12/2023 of stock options with underlying 3 common shares (exercise price shown as $0 after adjustments) and a separate option grant disclosing 1 underlying common share from a 05/31/2026-dated grant, both showing multi-year vesting schedules. The newly acquired common shares are restricted and subject to a lockup agreement entered in January 2025 that prevents sale for one year from 01/16/2025, with exceptions noted for shares from employment agreements.
Positive
- None.
Negative
- None.
Insights
TL;DR: Director reported a modest direct purchase of 42,194 shares and holds small adjusted option positions with multi-year vesting.
The transaction is an insider purchase recorded at a $2.37 per-share price, reflecting an explicit acquisition rather than an exercise-only disclosure. The filing documents significant historical reverse stock splits that materially adjusted option exercise prices and share counts; vesting schedules remain time-based over three years for the noted option grants. The lockup agreement on the restricted shares limits immediate liquidity for the reported block through early 2026, as described in the filing. Overall, the changes are routine insider activity with limited immediate market impact given the described restrictions and small adjusted option quantities.
TL;DR: Director-level purchase and option grants are disclosed with standard vesting and lockup terms; no governance anomalies are evident.
The report identifies the reporting person as a director and shows standard disclosures including direct ownership, option grants with cashless-exercise provisions (where permitted), and explicit lockup terms applied to the restricted shares. The document also transparently lists corporate actions that adjusted option figures (three reverse splits on specified dates). The filing appears compliant with Section 16 reporting requirements and includes the reporting person's manual signature.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 42,194 | $2.37 | $100K |
| Grant/Award | Stock Options | 3 | $0.00 | -- |
| holding | Stock Options | -- | -- | -- |
Footnotes (1)
- Represents Common Shares granted to the Reporting Person that are restricted and subject to a lockup agreement entered into by the Reporting Person in January 2025. Pursuant to the lockup agreement, the Reporting Person may not sell any Common Shares owned by the Reporting Person for one year from January 16, 2025 (subject to the ability to sell shares received by each as the result of an employment agreement at any time). Equals the per share closing price on September 17, 2025. As adjusted for the following: (i) a 1 for 50 reverse split that occurred on October 12, 2023, (ii) a 1 for 100 reverse split that occurred on December 6, 2024, and (iii) a 1 for 9 reverse split that occurred on July 30, 2025. The original exercise price was $0.09. If permitted by the policies of any stock exchange on which the Issuer may be listed from time to time, the stock option may be exercised by means of a "cashless exercise", in which event the Issuer shall issue to the holder the net number of common shares determined based on the formula presented in the exhibit to the stock option certificate. As adjusted for the following: (i) a 1 for 50 reverse split that occurred on October 12, 2023, (ii) a 1 for 100 reverse split that occurred on December 6, 2024, and (iii) a 1 for 9 reverse split that occurred on July 30, 2025. The original grant was 156,876 Stock Options. The shares subject to such option vest and become exercisable annually in substantially equal installments over a three-year period, with the first tranche to be vested on the three-month anniversary of date of grant of September 12, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date. As adjusted for the following: (i) a 1 for 50 reverse split that occurred on October 12, 2023, (ii) a 1 for 100 reverse split that occurred on December 6, 2024, and (iii) a 1 for 9 reverse split that occurred on July 30, 2025. The original exercise price was $7.00. The shares subject to such option vest and become exercisable annually in substantially equal installments over a three-year period, with the first tranche to be vested on the three-month anniversary of date of grant of May 31, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date. As adjusted for the following: (i) a 1 for 50 reverse split that occurred on October 12, 2023, (ii) a 1 for 100 reverse split that occurred on December 6, 2024, and (iii) a 1 for 9 reverse split that occurred on July 30, 2025. The original grant was 24,642 Stock Options.
